FYI: #GrossToNetBubble is alive and well. Here are UCB #drug pricing for 2024:
List prices: +5.0%
Net prices: -7.8%
Avg. reduction from list price: -54.1%
#DPFE #facts
buff.ly/3EQGG5l
FYI: #GrossToNetBubble is alive and well. Here are UCB #drug pricing for 2024:
List prices: +5.0%
Net prices: -7.8%
Avg. reduction from list price: -54.1%
#DPFE #facts
buff.ly/3EQGG5l
Warped incentives update: Stelara #biosimilars launching at deeply discounted WAC list prices. Will plan sponsors pop the #GrossToNetBubble and adopt?
More #PBM private labels coming soon...or maybe not given JNJ/Samsung lawsuit?
Source: drugch.nl/3Xkbi5Q
Surprise? PDPs use coinsurance more than MA-PD plans for high-list, high-rebate #GrossToNetBubble products. Result: Seniors pay a big share of net prices for so-called "preferred" #drugs.
Luckily, #IRA is tanking the PDP market π
Source: https://buff.ly/435aCoi
ICYMI: Latest Avalere analysis reveals that more than half of #generic #drugs are *not* on generic formulary tiers in 2025's Part D plans. Warped #GrossToNetBubble incentives remain despite #IRA.
==> https://buff.ly/49SOHlR
Inflation-Adjusted U.S. Brand-Name #Drug Prices Fell for the Seventh Consecutive Year as a New Era of Drug Pricing Dawns
Full details==> https://buff.ly/4093Pap
DCI's annual look at brand-name pricing shows how policy & channel strategies are popping the #GrossToNetBubble
h/t SSR Health
Fun fact: A growing number of brand-name #drugs have πππ
ππππ
list prices over the past 12+ months. That's the sound of the #GrossToNetBubble popping!
More on the new era for drug pricing coming Tuesday on ππ³πΆπ¨ ππ©π’π―π―π¦ππ΄.
h/t 46Brooklyn
Surprise? By the end of 2023, competition had reduced #Humira net #prescription prices by ~50% (& inflated the #GrossToNetBubble), despite minimal #biosimilar adoption.
P.S. In 2024, #PBM private labels started to pop the bubble.
==> drugch.nl/3DjRGHR
#PBM Power: The Gross-to-Net Bubble Reached $334 Billion in 2023βBut Will Soon Start Deflating (rerun)
==> drugch.nl/3ZsxECg
DCI's most recent update on our infamous term
#SpongeBob25 #GrossToNetBubble
Sanofi's gap between avg US list and net prices was 19+ percentage points in 2023 - largest since before 2016. Also largest gap ever for insulins?
#grosstonetbubble